Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

High‐risk neuroblastoma, a predominantly TP53 wild‐type (wt) tumour, is incurable in >50% patients supporting the use of MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat neuroblastoma. This is the first study to evaluate the in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Cancer
Hoofdauteurs: Chen, Lindi, Pastorino, Fabio, Berry, Philip, Bonner, Jennifer, Kirk, Calum, Wood, Katrina M., Thomas, Huw D., Zhao, Yan, Daga, Antonio, Veal, Gareth J., Lunec, John, Newell, David R., Ponzoni, Mirco, Tweddle, Deborah A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2019
Onderwerpen:
Cancer Therapy and Prevention
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6491995/
https://ncbi.nlm.nih.gov/pubmed/30536898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32058
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items